Xultophy (liraglutide insulin degludec): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Xultophy 100 units/ml insulin degludec + 3.6 mg/mL liraglutide solution for injection in a pre-filled pen

Xultophy is indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).


Route of administration: Injectable
Molecule: liraglutide, insulin degludec

Patients' opinions on Xultophy

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Diabetes (Type 2)

See the fact sheet